Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
First Claim
Patent Images
1. A method for treating retinal degeneration in a subject in need thereof, comprising:
- (a) producing an enriched population of human retinal epithelium (RPE) cells by;
(i) providing a multilayer population of human embryonic stem (hES) cells;
(ii) culturing said multilayer population of hES cells under conditions that do not maintain the undifferentiated state of said hES cells for a sufficient time for the appearance of putative human RPE cells, wherein said putative human RPE cells comprise brown pigment dispersed within their cytoplasm;
(iii) selecting one or more of said putative human RPE cells from the culture of step (ii) to obtain human RPE cells; and
(iv) culturing said human RPE cells selected in step (iii) to form a cell monolayer containing cells that are Pax6− and
bestrophin+ and exhibit a characteristic cobblestone, polygonal, epithelial-like appearance and comprise brown pigment dispersed within their cytoplasm; and
(b) administering to an eye of a subject in need thereof the human RPE cells produced in step (a), thereby treating retinal degeneration in said subject.
7 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
41 Citations
68 Claims
-
1. A method for treating retinal degeneration in a subject in need thereof, comprising:
-
(a) producing an enriched population of human retinal epithelium (RPE) cells by; (i) providing a multilayer population of human embryonic stem (hES) cells; (ii) culturing said multilayer population of hES cells under conditions that do not maintain the undifferentiated state of said hES cells for a sufficient time for the appearance of putative human RPE cells, wherein said putative human RPE cells comprise brown pigment dispersed within their cytoplasm; (iii) selecting one or more of said putative human RPE cells from the culture of step (ii) to obtain human RPE cells; and (iv) culturing said human RPE cells selected in step (iii) to form a cell monolayer containing cells that are Pax6− and
bestrophin+ and exhibit a characteristic cobblestone, polygonal, epithelial-like appearance and comprise brown pigment dispersed within their cytoplasm; and(b) administering to an eye of a subject in need thereof the human RPE cells produced in step (a), thereby treating retinal degeneration in said subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
-
21. A method for treating retinal degeneration in a subject in need thereof, comprising:
-
(a) producing an enriched population of human RPE cells by; (i) providing a culture of hES cells; (ii) culturing the hES cells to produce one or more embryoid bodies; (iii) culturing said one or more embryoid bodies under conditions that do not maintain the undifferentiated state of said hES cells for a sufficient time for the appearance of putative human RPE cells within at least one of said one or more embryoid bodies, wherein said putative human RPE cells comprise brown pigment dispersed within their cytoplasm; (iv) selecting and dissociating one or more of said embryoid bodies containing putative human RPE cells from the culture of step (iii) to obtain human RPE cells; and (v) culturing said human RPE cells selected in step (iv) to form a cell monolayer containing cells that are Pax6− and
bestrophin+ and exhibit a characteristic cobblestone, polygonal, epithelial-like appearance and comprise brown pigment dispersed within their cytoplasm; and(b) administering to an eye of a subject in need thereof the human RPE cells produced in step (a), thereby treating retinal degeneration in said subject. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method for treating retinal degeneration in a subject in need thereof, comprising:
-
(a) producing an enriched population of human RPE cells by; (i) providing a multilayer population of hES cells, wherein said multilayer population of hES cells has been cultured in media containing exogenously added FGF; (ii) culturing said multilayer population of hES cells under conditions that do not maintain the undifferentiated state of said hES cells for a sufficient time for the appearance of putative human RPE cells, wherein said putative human RPE cells comprise brown pigment dispersed within their cytoplasm, wherein said conditions that do not maintain the undifferentiated state of said hES cells comprise media lacking exogenously added FGF and the duration of culturing is at least 6 weeks; (iii) selecting one or more of said putative human RPE cells from the culture of step (ii) to obtain human RPE cells; and (iv) culturing said human RPE cells selected in step (iii) to form a cell monolayer containing cells that are Pax6−
, bestrophin+, CRALBP+, PEDF+, and express RPE65, have the absence of at least one ES cell marker selected from the group consisting of Oct4, Sox2, and TDGF-1, and exhibit a characteristic cobblestone, polygonal, epithelial-like appearance and comprise brown pigment dispersed within their cytoplasm, wherein during said culturing the cultured cells temporarily lose their epithelial appearance and pigmentation after plating, and then regain their epithelial appearance and pigmentation upon further culturing; and(b) administering to an eye of a subject in need thereof the human RPE cells produced in step (a), thereby treating retinal degeneration in said subject. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
-
-
55. A method for treating retinal degeneration in a subject in need thereof, comprising:
-
(a) producing an enriched population of human RPE cells by; (i) providing a culture of hES cells; (ii) culturing the hES cells to produce one or more embryoid bodies, wherein said one or more embryoid bodies or the cells from which said one or more embryoid bodies are formed have been cultured in media containing exogenously added FGF; (iii) culturing said one or more embryoid bodies for a sufficient time for the appearance of putative human RPE cells within at least one of said one or more embryoid bodies, wherein said putative human RPE cells comprise brown pigment dispersed within their cytoplasm, wherein the one or more embryoid bodies are cultured in a media lacking exogenously added FGF, and the duration of culturing is at least 6 weeks, whereby one or more embryoid bodies containing putative human RPE cells are formed; (iv) selecting and dissociating one or more of said embryoid bodies containing putative human RPE cells from the culture of step (iii) to obtain human RPE cells; and (v) culturing said human RPE cells selected in step (iv) to form a cell monolayer containing cells that are Pax6−
, bestrophin+, CRALBP+, PEDF+, and express RPE65, have the absence of at least one ES cell marker selected from the group consisting of Oct4, Sox2 and TDGF-1, and exhibit a characteristic cobblestone, polygonal, epithelial-like appearance and comprise brown pigment dispersed within their cytoplasm, wherein during said culturing the cultured cells temporarily lose their epithelial appearance and pigmentation after plating, and then regain their epithelial appearance and pigmentation upon further culturing; and(b) administering to an eye of a subject in need thereof the human RPE cells produced in step (a), thereby treating retinal degeneration in said subject. - View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
-
Specification